ArticleDrug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy
Repositioning chloroquine and metformin to eliminate cancer stem cell traits in pre-malignant lesions.
Article in Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 64 citations in OpenAlex.
- Drug-drug interactions with candidate medications used for COVID-19 treatment: An overview.Pharmacology research & perspectives · 2021Review
- Co-targeting of lysosome and mitophagy in cancer stem cells with chloroquine analogues and antibiotics.Journal of cellular and molecular medicine · 2020Review
- Correlation of NRF2 and progesterone receptor and its effects on ovarian cancer biology.Cancer management and research · 2019Article
- Targeting cancer stem cells with dietary phytochemical - Repositioned drug combinations.Cancer letters · 2018Article
- Metformin, the aspirin of the 21st century: its role in gestational diabetes mellitus, prevention of preeclampsia and cancer, and the promotion of longevity.American journal of obstetrics and gynecology · 2017Review
- Genetic ablation or pharmacologic inhibition of autophagy mitigated NSAID-associated gastric damages.Journal of molecular medicine (Berlin, Germany) · 2017Article
- Mitigated NSAID-induced apoptotic and autophagic cell death with Smad7 overexpression.Journal of clinical biochemistry and nutrition · 2017Article
- Metformin represses bladder cancer progression by inhibiting stem cell repopulation via COX2/PGE2/STAT3 axis.Oncotarget · 2016Article
- Drug Delivery Using Nanoparticles for Cancer Stem-Like Cell Targeting.Frontiers in pharmacology · 2016Review
- Opportunities and challenges of radiotherapy for treating cancer.Nature reviews. Clinical oncology · 2015Review
- Breast Cancer Metabolism and Mitochondrial Activity: The Possibility of Chemoprevention with Metformin.BioMed research international · 2015Review
- Inhibitory effect of chloroquine derivatives on presenilin 1 and ubiquilin 1 expression in Alzheimer's disease.International journal of clinical and experimental pathology · 2015Article
- Anti-protozoal and anti-bacterial antibiotics that inhibit protein synthesis kill cancer subtypes enriched for stem cell-like properties.Cell cycle (Georgetown, Tex.) · 2015Article
- Induced cancer stem-like cells as a model for biological screening and discovery of agents targeting phenotypic traits of cancer stem cell.Oncotarget · 2014Article
- The nutritional phenome of EMT-induced cancer stem-like cells.Oncotarget · 2014Article
- Chemoquiescence for ideal cancer treatment and prevention: where are we now?Journal of cancer prevention · 2014Review
- Targeting of preexisting and induced breast cancer stem cells with trastuzumab and trastuzumab emtansine (T-DM1).Cell death & disease · 2014Article
- Metabostemness: a new cancer hallmark.Frontiers in oncology · 2014Review
- Chloroquine has tumor-inhibitory and tumor-promoting effects in triple-negative breast cancer.Oncology letters · 2013Article
- The Warburg effect version 2.0: metabolic reprogramming of cancer stem cells.Cell cycle (Georgetown, Tex.) · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 1 country.
Funding
Abstract
Ideal oncology drugs would be curative after a short treatment course if they could eliminate epithelium-originated carcinomas at their non-invasive, pre-malignant stages. Such ideal molecules, which are expected to molecularly abrogate all the instrumental mechanisms acquired by migrating cancer stem cells (CSCs) to by-pass tumour suppressor barriers, might already exist. We here illustrate how system biology strategies for repositioning existing FDA-approved drugs may accelerate our therapeutic capacity to eliminate CSC traits in pre-invasive intraepithelial neoplasias. First, we describe a signalling network signature that overrides bioenergetics stress- and oncogene-induced senescence (OIS) phenomena in CSCs residing at pre-invasive lesions. Second, we functionally map the anti-malarial chloroquine and the anti-diabetic metformin ("old drugs") to their recently recognized CSC targets ("new uses") within the network. By discussing the preclinical efficacy of chloroquine and metformin to inhibiting the genesis and self-renewal of CSCs we finally underscore the expected translational impact of the "old drugs-new uses" repurposing strategy to open a new CSC-targeted chemoprevention era.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.